Comparative impact on islet isolation and transplant outcome of the preservation solutions Institut Georges Lopez-1, University of Wisconsin, and Celsior

Transplantation. 2012 Apr 15;93(7):703-8. doi: 10.1097/TP.0b013e3182476cc8.

Abstract

Background: Institut Georges Lopez-1 (IGL-1) is a preservation solution similar to University of Wisconsin (UW) with reversed Na/K contents. In this study, we assessed the impact of IGL-1, UW, and Celsior (CS) solutions on islet isolation and transplant outcome.

Methods: We retrospectively analyzed 376 islet isolations from pancreases flushed and transported with IGL-1 (n=95), UW (n=204), or CS (n=77). We determined isolation outcome and β-cell function in vitro. Transplanted patients were divided into three groups depending on preservation solution of pancreas, and islet graft function was assessed by decrease in daily insulin needs, C-peptide/glucose ratios, β-scores, and transplant estimated function at 1- and 6-month follow-up.

Results: IGL-1, UW, and CS groups were similar according to donor age, body mass index, and pancreas weight. There was no difference in islet yields between the three groups. Success rates, transplant rates, β-cell secretory function, and viability were similar for all three groups. We observed no difference in decreased insulin needs, C-peptide glucose ratios, β-scores, and transplant estimated function at 1- and 6-month follow-up between IGL-1, UW, and CS groups.

Conclusions: Our study shows that IGL-1 is equivalent to UW or CS solutions for pancreas perfusion and cold storage before islet isolation and transplantation.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine / therapeutic use
  • Adult
  • Allopurinol / therapeutic use
  • Analysis of Variance
  • Biomarkers / blood
  • Blood Glucose / metabolism
  • C-Peptide / blood
  • Chi-Square Distribution
  • Diabetes Mellitus / blood
  • Diabetes Mellitus / drug therapy
  • Diabetes Mellitus / surgery*
  • Disaccharides / therapeutic use
  • Electrolytes / therapeutic use
  • Female
  • Glutamates / therapeutic use
  • Glutathione / therapeutic use
  • Glycated Hemoglobin / metabolism
  • Histidine / therapeutic use
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Insulin / therapeutic use
  • Islets of Langerhans / drug effects*
  • Islets of Langerhans / metabolism
  • Islets of Langerhans Transplantation*
  • Male
  • Mannitol / therapeutic use
  • Middle Aged
  • Organ Preservation / methods*
  • Organ Preservation Solutions / therapeutic use*
  • Raffinose / therapeutic use
  • Retrospective Studies
  • Time Factors
  • Tissue Culture Techniques
  • Tissue and Organ Harvesting / methods*
  • Treatment Outcome

Substances

  • Biomarkers
  • Blood Glucose
  • C-Peptide
  • Celsior
  • Disaccharides
  • Electrolytes
  • Glutamates
  • Glycated Hemoglobin A
  • Hypoglycemic Agents
  • IGL-1 solution
  • Insulin
  • Organ Preservation Solutions
  • University of Wisconsin-lactobionate solution
  • hemoglobin A1c protein, human
  • Mannitol
  • Histidine
  • Allopurinol
  • Glutathione
  • Adenosine
  • Raffinose